ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      6,037.59
      1.06%
      US Tech 100
      21,180.00
      -0.09%
      Dow Jones
      43,325.80
      0.07%
      Brent Oil
      72.89
      0.00%
      Bitcoin
      95,663.83
      -0.02%
      Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Humacyte Inc (HUMA) Quote

      Humacyte Inc

      Humacyte Inc (HUMA)

      NASDAQ
      5.29
      0.78
      (17.29%)
      At close: December 26 4:00PM
      Delayed by 15 minutes
      5.34
      0.05
      ( 0.95% )
      After Hours: 6:55PM
      Delayed by 15 minutes

      Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

      Premium

      Key stats and details

      Current Price
      5.34
      Bid
      5.32
      Ask
      5.34
      Volume
      11,661,307
      4.40 Day's Range 5.3031
      2.48 52 Week Range 9.97
      Market Cap
      672.09M
      Previous Close
      4.51
      Open
      4.50
      Last Trade
      1
      @
      5.33
      Last Trade Time
      18:57:04
      Financial Volume
      $ 58,866,210
      VWAP
      5.048
      Average Volume (3m)
      4,418,603
      Shares Outstanding
      125,859,496
      Dividend Yield
      -
      PE Ratio
      -12.45
      Earnings Per Share (EPS)
      -0.88
      Revenue
      -
      Net Profit
      -110.78M

      About Humacyte Inc

      Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases,... Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      www.humacyte.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Humacyte Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker HUMA. The last closing price for Humacyte was $4.51. Over the last year, Humacyte shares have traded in a share price range of $ 2.48 to $ 9.97.

      Humacyte currently has 125,859,496 shares outstanding. The market capitalization of Humacyte is $567.63 million. Humacyte has a price to earnings ratio (PE ratio) of -12.45.

      Ask ADVFN Intelligence (AI)

      Humacyte (HUMA) Options Flow Summary

      HUMA Options Flow

      Overall Flow

      Bearish

      Net Premium

      -7k

      Calls / Puts

      100,00%

      Buys / Sells

      100,00%

      OTM / ITM

      100,00%

      Sweeps Ratio

      0,00%

      HUMA Latest News

      More News

      Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

      Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA PR Newswire NEW YORK, Dec. 26, 2024 NEW YORK, Dec. 26, 2024...

      13 hours ago
      PR Newswire (US)

      Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

      Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- The...

      December 23 2024
      PR Newswire (US)

      Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

      Investors in Humacyte, Inc. Should Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA PR Newswire NEW YORK, Dec. 19, 2024 NEW YORK, Dec. 19, 2024 /PRNewswire/ -- The...

      December 19 2024
      PR Newswire (US)

      Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA

      Humacyte, Inc. Sued for Securities Law Violations - Contact The Gross Law Firm Before January 17, 2025 to Discuss Your Rights - HUMA PR Newswire NEW YORK, Dec. 16, 2024 NEW YORK, Dec. 16, 2024...

      December 16 2024
      PR Newswire (US)

      Class Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact The Gross Law Firm

      Class Action Filed Against Humacyte, Inc. (HUMA) - January 17, 2025 Deadline to Join - Contact The Gross Law Firm PR Newswire NEW YORK, Dec. 12, 2024 NEW YORK, Dec. 12, 2024 /PRNewswire/ -- The...

      December 12 2024
      PR Newswire (US)

      The Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA

      The Gross Law Firm Reminds Humacyte, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of January 17, 2025 - HUMA PR Newswire NEW YORK, Dec. 9, 2024 NEW YORK, Dec...

      December 09 2024
      PR Newswire (US)

      The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit - HUMA

      The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 17, 2025 in Humacyte, Inc. Lawsuit - HUMA PR Newswire NEW YORK, Dec. 5, 2024 NEW YORK, Dec. 5, 2024 /PRNewswire/...

      December 05 2024
      PR Newswire (US)

      The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders

      The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Humacyte, Inc.(HUMA) Shareholders PR Newswire NEW YORK, Nov. 22, 2024 NEW YORK, Nov. 22, 2024 /PRNewswire/ -- The...

      November 22 2024
      PR Newswire (US)

      Form 4 - Statement of changes in beneficial ownership of securities

      September 03 2024
      Edgar (US Regulatory)

      Form 4 - Statement of changes in beneficial ownership of securities

      September 03 2024
      Edgar (US Regulatory)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      11.7749.57983193283.576.773.37230914934.60139074CS
      40.8619.19642857144.486.773.3771715884.48250822CS
      12-0.21-3.783783783785.556.773.3744186034.80798931CS
      260.418.316430020284.939.793.3737663725.64361938CS
      522.4685.41666666672.889.972.4826963245.48628134CS
      156-2.61-32.83018867927.959.971.9611882095.09344583CS
      260-4.66-46.61017.451.9611194905.3377848CS

      HUMA - Frequently Asked Questions (FAQ)

      What is the current Humacyte share price?
      The current share price of Humacyte is $ 5.34
      How many Humacyte shares are in issue?
      Humacyte has 125,859,496 shares in issue
      What is the market cap of Humacyte?
      The market capitalisation of Humacyte is USD 567.63M
      What is the 1 year trading range for Humacyte share price?
      Humacyte has traded in the range of $ 2.48 to $ 9.97 during the past year
      What is the PE ratio of Humacyte?
      The price to earnings ratio of Humacyte is -12.45
      What is the reporting currency for Humacyte?
      Humacyte reports financial results in USD
      What is the latest annual profit for Humacyte?
      The latest annual profit of Humacyte is USD -110.78M
      What is the registered address of Humacyte?
      The registered address for Humacyte is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
      What is the Humacyte website address?
      The website address for Humacyte is www.humacyte.com
      Which industry sector does Humacyte operate in?
      Humacyte operates in the BIOLOGICAL PDS,EX DIAGNSTICS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      TOIIWOncology Institute Inc
      $ 0.0197
      (109.57%)
      		42.81k
      EVAXEvaxion Biotech AS
      $ 1.58
      (86.76%)
      		6.98M
      RVSNRail Vision Ltd
      $ 1.20
      (55.12%)
      		6.97M
      INTZIntrusion Inc
      $ 0.695
      (54.44%)
      		3.29M
      JSPRWJasper Therapeutics Inc
      $ 0.25
      (47.06%)
      		343
      MITAColiseum Acquisition Corporation
      $ 9.00
      (-21.81%)
      		11.88k
      VIRXViracta Therapeutics Inc
      $ 0.1875
      (-20.89%)
      		420.06k
      SPRCSciSparc Ltd
      $ 0.4255
      (-14.90%)
      		1.8M
      BDRXBiodexa Pharmaceuticals PLC
      $ 4.04
      (-14.04%)
      		4.42k
      SLGLSol Gel Technologies Ltd
      $ 1.07
      (-12.30%)
      		32.99k
      CRKNCrown Electrokinetics Corporation
      $ 0.161
      (22.25%)
      		36.46M
      OMEXOdyssey Marine Exploration Inc
      $ 0.6446
      (34.15%)
      		9.7M
      QSIQuantum Si Inc
      $ 2.45
      (13.95%)
      		8.27M
      XTIAXTI Aerospace Inc
      $ 0.03995
      (-0.13%)
      		7.69M
      EVAXEvaxion Biotech AS
      $ 1.58
      (86.76%)
      		6.98M

      HUMA Discussion

      View Posts
      threebabiesbusy threebabiesbusy 2 days ago
      Humacyte price target raised to $17 from $15 at Benchmark. Looking forward to 2025. Insider buying and pt upgrades bode well for positive moves going forward.
      GLTA
      3
      👍 1
      sblzng sblzng 3 days ago
      It's gonna go .Interest is picking up and more buys than sells
      👍️0
      Monksdream Monksdream 5 days ago
      HUMA under $5

      [color=red][/color]
      👍️0
      threebabiesbusy threebabiesbusy 6 days ago
      Wainwright analyst Vernon Bernardino raised the firm's price target on Humacyte (HUMA) to $15 from $12 and keeps a Buy rating on the shares after the FDA granted full approval for Symvess for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb ...
      👍️0
      threebabiesbusy threebabiesbusy 6 days ago
      Let's push through the $4.80 wall!
      👍️0
      threebabiesbusy threebabiesbusy 6 days ago
      awww so you're out. Looks difficult for afternoon move up
      👍️0
      threebabiesbusy threebabiesbusy 6 days ago
      We're trading substantially below days VWAP....
      👍️0
      threebabiesbusy threebabiesbusy 6 days ago
      Lunch time pull back. Do you anticipate afternoon trend back up? Or do we call it one and done!
      👍️0
      TrendTrade2016 TrendTrade2016 6 days ago
      EXITED ON THAT PUSH BOTTOM BOUNCE
      👍️0
      Tiger Money Tiger Money 6 days ago
      Love having you back.  You are one of the smartest traders out there.  Unfortunately you like to be mean to less intelligent people 😝.  Anyways, how far do you think this could run?  Thanks
      👍️0
      FooBarAndGrill FooBarAndGrill 6 days ago
      Now, reality bites.
      Cash and time to ramp up.
      Will vascular surgeons switch from the old and familiar?
      TBD.
      👍️0
      TrendTrade2016 TrendTrade2016 6 days ago
      HUMA READY TO RUN AGAIN
      👍️0
      Tiger Money Tiger Money 6 days ago
      Finally!
      👍️ 1
      FooBarAndGrill FooBarAndGrill 7 days ago
      Approved
      https://investors.humacyte.com/news-releases/news-release-details/humacyte-announces-fda-approval-symvesstm-acellular-tissue
      👍️ 1
      FooBarAndGrill FooBarAndGrill 2 weeks ago
      Today is Dec 9th. Dec 9th marks 10 months since HUMA's PDUFA application.
      FDA has performance goals. For regular PDUFA applications the goal is 90% within 10 months.
      FDA performance goals: https://www.fda.gov/media/151712/download
      👍️0
      FooBarAndGrill FooBarAndGrill 2 weeks ago
      I don't know of any. But you can roll your own using eg. Amazon Transcribe.
      👍️0
      tm100 tm100 2 weeks ago
      Is there a transcript available anywhere? Have not had any success finding a transcript
      👍️0
      Tiger Money Tiger Money 3 weeks ago
      Good news that they don't pull the plug.  This will be accepted by RFK less than a month in office 
      👍️0
      FooBarAndGrill FooBarAndGrill 3 weeks ago
      The FDA is the wall. She can't say anything.
      Adding that FDA has performance goals which, in this case, are not being met.
      👍️0
      Tiger Money Tiger Money 3 weeks ago
      You say ok.  So everything is moving forward with the fda still?  Thanks 
      👍️0
      FooBarAndGrill FooBarAndGrill 3 weeks ago
      Webcast OK. Direct questions and direct answers.
      👍️0
      FooBarAndGrill FooBarAndGrill 3 weeks ago
      Supplemental BLA. Discussed during webcast.
      Replay is up. https://investors.humacyte.com/news-events/events-and-presentations
      👍️0
      Tiger Money Tiger Money 3 weeks ago
      If they are selling for any other reason than to keep it below 5%, there will be a ton of lawsuits....
      👍️0
      FooBarAndGrill FooBarAndGrill 3 weeks ago
      Stonewalled.
      The family sold with the excuse to reduce below 5% holding. That's no excuse at all. They're still insiders and know exactly what's up.
      👍️0
      Tiger Money Tiger Money 3 weeks ago
      Crazy
      👍️0
      FooBarAndGrill FooBarAndGrill 4 weeks ago
      $HUMA It's all in the family:
      Mr. Dougan is married to Dr. Niklason and Mr. Dougan has sole voting and dispositive power over the shares held by Ayabudge LLC. By virtue of these relationships, Mr. Dougan may be deemed to share beneficial ownership of the securities held of record by Dr. Niklason, The Niklason Living Trust and Ayabudge LLC.
      👍️0
      Tiger Money Tiger Money 1 month ago
      Great color!  Time for the fda to let this run
      👍️0
      roadkilll roadkilll 2 months ago
      Department of Defense's priority designation is a strong tell about the future of civilian use.
      "Humacyte is currently evaluating the HAV in a phase 2/3 clinical trial in vascular trauma for use as a vascular replacement to restore blood flow to a limb when saphenous veins or synthetic grafts are not feasible. The HAV has received priority designation for the treatment of vascular trauma by the United States Secretary of Defense."
      Sept 22, 2023 article
      .
      after approval expect a quick order from DOD
      👍️0
      roadkilll roadkilll 2 months ago
      A RMAT designation allows for accelerated approval based surrogate or intermediate endpoints. RMAT goes beyond breakthrough therapy features by allowing for accelerated approval of drugs based on surrogate endpoints. A surrogate endpoint is a biomarker that substitutes for a direct endpoint, such as clinical benefit.
      .
      FDA has awarded Humacyte for two indications.
      👍️0
      Monksdream Monksdream 2 months ago
      HUMA under $6
      👍️0
      FooBarAndGrill FooBarAndGrill 2 months ago
      Has ANYTHING changed?
      August 9, 2024 “We received a call from FDA CBER leadership this afternoon apologizing to us and stating that additional time was required for review.”
      👍️0
      Tiger Money Tiger Money 3 months ago
      This company has a lot going for it, that is for sure
      👍️0
      FooBarAndGrill FooBarAndGrill 3 months ago
      Humacyte up today on genuinely positive SA piece.
      https://seekingalpha.com/article/4722917-humacyte-navigating-the-fda-uncertainty-and-atevs-potential
      👍️0
      Tiger Money Tiger Money 3 months ago
      Very nice!
      👍️0
      Sirpeter Sirpeter 3 months ago
      Wynn for the win...my horse is coming in
      👍️0
      Tiger Money Tiger Money 3 months ago
      Great to hear from you. I bought a bunch of calls for 5 cents here for he t week expiry. I can only hope Christmas comes early…
      👍️0
      Sirpeter Sirpeter 3 months ago
      How are ya bud...been busy...Sept sucks for stocks...only holding some WYNN calls until interest rate cuts on the 18th...have to remember to ck in once in here a while lol...hope all is good with you...talk again soon
      👍️0
      Tiger Money Tiger Money 3 months ago
      You still around? I have a feeling go time could be soon but fda always has em all by the balls ….
      👍️0
      Tiger Money Tiger Money 4 months ago
      Likey or dislikey? Just waiting on fda. Tech is there, proven and safe. A lot of limbs/lives saved in Ukraine because of humacyte
      👍️0
      Monksdream Monksdream 4 months ago
      HUMA under $7

      👍️0
      Tiger Money Tiger Money 4 months ago
      Their product is amazing. Will help so many people
      👍️0
      Tiger Money Tiger Money 4 months ago
      Great stuff and that is what I see too. Thanks!
      👍️0
      Sirpeter Sirpeter 4 months ago
      I sold my options here and bought shares...they're cheap
      👍️0
      Stern is Bald Stern is Bald 4 months ago
      Very promising stock and the is an opportunity to buy the dip big time..
      👍️0
      Tiger Money Tiger Money 4 months ago
      Ok, now that is cleared up. In all seriousness, looking for your thoughts on huma . Thanks and appreciate and hope we can work together to make some $
      👍️0
      Stern is Bald Stern is Bald 4 months ago
      Just nonsensical jibberish about deep state blah blah blah… either wat i am 90% of tuning out the knuckleheads on this site… glad you put it out there like that easier to know not to take anything from you very seriously…
      👍️0
      Tiger Money Tiger Money 4 months ago
      Not sure I have been called Jesus before especially since I’m not Spanish.
      👍️0
      Tiger Money Tiger Money 4 months ago
      What? You didn’t like the coup?
      👍️0
      Stern is Bald Stern is Bald 4 months ago
      Man are you dumb jesus…
      👍️0
      Sirpeter Sirpeter 4 months ago
      Think the dumbacrats are here to stay...will see
      👍️0

      Your Recent History

      NASDAQ
      HUMA
      Humacyte
      BOV
      BMEB4R
      BANCO MERCANTIL PN
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads